<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">One large case series and 2 registries have reported a combined total of 721 confirmed or highly suspected cases of COVID-19 in adult and pediatric immune-mediated inflammatory disease populations through May 19, 2020.
 <xref rid="bib71" ref-type="bibr">71</xref>, 
 <xref rid="bib72" ref-type="bibr">72</xref>, 
 <xref rid="bib73" ref-type="bibr">73</xref> The results are summarized in 
 <xref rid="tbl2" ref-type="table">Table II</xref> .
 <xref rid="bib71" ref-type="bibr">71</xref>, 
 <xref rid="bib72" ref-type="bibr">72</xref>, 
 <xref rid="bib73" ref-type="bibr">73</xref> Haberman etÂ al
 <xref rid="bib71" ref-type="bibr">
  <sup>71</sup>
 </xref> noted that those requiring hospitalization were more likely to have rheumatoid arthritis, had more comorbidities, were older, and had greater use of methotrexate, hydroxychloroquine, and corticosteroids. They also reported an overall incidence of hospitalization of 16%, which was comparable to the 26% incidence in patients with COVID-19 in the general population in New York.
 <xref rid="bib71" ref-type="bibr">
  <sup>71</sup>
 </xref> They concluded that baseline use of biologics was not associated with worse COVID-19 outcomes.
</p>
